ATROPINE

Atropine Adverse Events Reported to the FDA Over Time

How are Atropine adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Atropine, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Atropine is flagged as the suspect drug causing the adverse event.

Most Common Atropine Adverse Events Reported to the FDA

What are the most common Atropine adverse events reported to the FDA?

Completed Suicide	64 (1.97%)
Bradycardia	38 (1.17%)
Drug Rash With Eosinophilia And Sys...	37 (1.14%)
Agitation	33 (1.02%)
Drug Ineffective	33 (1.02%)
Mydriasis	33 (1.02%)
Vomiting	33 (1.02%)
Nausea	30 (.92%)
Tachycardia	30 (.92%)
Respiratory Arrest	29 (.89%)
Cardiac Arrest	28 (.86%)
	Show More
Confusional State	27 (.83%)
Ventricular Tachycardia	27 (.83%)
Convulsion	26 (.8%)
Hypotension	26 (.8%)
Pyrexia	25 (.77%)
Disseminated Intravascular Coagulat...	24 (.74%)
Blood Pressure Decreased	23 (.71%)
Constipation	23 (.71%)
Dyspnoea	23 (.71%)
Flushing	23 (.71%)
Headache	23 (.71%)
Oxygen Saturation Decreased	23 (.71%)
Toxic Encephalopathy	23 (.71%)
Drug Toxicity	22 (.68%)
Medication Error	21 (.65%)
Dehydration	20 (.62%)
Disorientation	20 (.62%)
Death	19 (.59%)
Erythema	19 (.59%)
Rash	19 (.59%)
Ventricular Fibrillation	19 (.59%)
Weight Decreased	19 (.59%)
Hypertension	18 (.55%)
Delirium	17 (.52%)
Heart Rate Increased	17 (.52%)
Sinus Tachycardia	17 (.52%)
Tachypnoea	17 (.52%)
Asthenia	16 (.49%)
Cardio-respiratory Arrest	16 (.49%)
Diarrhoea	16 (.49%)
Hallucination	15 (.46%)
Multiple Drug Overdose	15 (.46%)
Toxic Epidermal Necrolysis	15 (.46%)
Blood Pressure Increased	14 (.43%)
Coma	14 (.43%)
Depression	14 (.43%)
Hallucination, Visual	14 (.43%)
Loss Of Consciousness	14 (.43%)
Renal Failure Acute	14 (.43%)
Shock	14 (.43%)
Somnolence	14 (.43%)
Stress Cardiomyopathy	14 (.43%)
Vision Blurred	14 (.43%)
Visual Impairment	14 (.43%)
Accidental Overdose	13 (.4%)
Decreased Appetite	13 (.4%)
Mental Status Changes	13 (.4%)
Overdose	13 (.4%)
Pain	13 (.4%)
Respiratory Failure	13 (.4%)
Torsade De Pointes	13 (.4%)
Urinary Tract Infection	13 (.4%)
Anaphylactic Shock	12 (.37%)
Circulatory Collapse	12 (.37%)
Condition Aggravated	12 (.37%)
Drug Interaction	12 (.37%)
Dry Mouth	12 (.37%)
Fall	12 (.37%)
Heart Rate Decreased	12 (.37%)
Malaise	12 (.37%)
Pulmonary Oedema	12 (.37%)
Respiratory Depression	12 (.37%)
Acute Pulmonary Oedema	11 (.34%)
Blindness	11 (.34%)
Cardiac Failure	11 (.34%)
Cardiac Procedure Complication	11 (.34%)
Fatigue	11 (.34%)
Haemoglobin Decreased	11 (.34%)
Hypersensitivity	11 (.34%)
Laryngeal Oedema	11 (.34%)
Muscular Weakness	11 (.34%)
Oliguria	11 (.34%)
Drug Hypersensitivity	10 (.31%)
Electrocardiogram Qt Prolonged	10 (.31%)
Haemodynamic Instability	10 (.31%)
Hypoxia	10 (.31%)
Insomnia	10 (.31%)
Miosis	10 (.31%)
Syncope	10 (.31%)
Tremor	10 (.31%)
Abdominal Distension	9 (.28%)
Anticholinergic Syndrome	9 (.28%)
Atrial Fibrillation	9 (.28%)
Bronchospasm	9 (.28%)
Dizziness	9 (.28%)
Haematuria	9 (.28%)
Long Qt Syndrome	9 (.28%)
Photophobia	9 (.28%)
Pruritus	9 (.28%)
Ventricular Arrhythmia	9 (.28%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Atropine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Atropine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Atropine

What are the most common Atropine adverse events reported to the FDA?

Cardiac Arrhythmias	250 (7.7%)
Respiratory	171 (5.27%)
Epidermal And Dermal Conditions	154 (4.75%)
Neurological	141 (4.35%)
Medication Errors	109 (3.36%)
Cardiac And Vascular Investigations	107 (3.3%)
Gastrointestinal Signs	97 (2.99%)
Suicidal And Self-injurious Behavio...	77 (2.37%)
Deliria	64 (1.97%)
Therapeutic And Nontherapeutic Effe...	64 (1.97%)
Infections - Pathogen Unspecified	62 (1.91%)
	Show More
Procedural And Device Related Injur...	62 (1.91%)
Ocular Neuromuscular	56 (1.73%)
Decreased And Nonspecific Blood Pre...	55 (1.69%)
Allergic Conditions	48 (1.48%)
Vision	48 (1.48%)
Anxiety Disorders	44 (1.36%)
Gastrointestinal Motility And Defec...	42 (1.29%)
Lower Respiratory Tract Disorders	41 (1.26%)
Movement Disorders	39 (1.2%)
Vascular	39 (1.2%)
Hematology Investigations	38 (1.17%)
Injuries	37 (1.14%)
Body Temperature Conditions	36 (1.11%)
Fatal Outcomes	35 (1.08%)
Renal Disorders	34 (1.05%)
Coronary Artery	33 (1.02%)
Administration Site Reactions	32 (.99%)
Disturbances In Thinking	32 (.99%)
Chemical Injury And Poisoning	30 (.92%)
Muscle	29 (.89%)
Encephalopathies	28 (.86%)
Physical Examination Topics	28 (.86%)
Seizures	28 (.86%)
Electrolyte And Fluid Balance Condi...	27 (.83%)
Metabolic, Nutritional And Blood Ga...	27 (.83%)
Upper Respiratory Tract Disorders	27 (.83%)
Coagulopathies And Bleeding Diathes...	26 (.8%)
Hepatic And Hepatobiliary	26 (.8%)
Heart Failures	24 (.74%)
Psychiatric	24 (.74%)
Headaches	23 (.71%)
Ocular Infections, Irritations And ...	22 (.68%)
Urinary Tract Signs	22 (.68%)
Appetite And General Nutritional	21 (.65%)
Bronchial Disorders	21 (.65%)
Central Nervous System Vascular	19 (.59%)
Vascular Hypertensive	19 (.59%)
Cardiac Disorder Signs	17 (.52%)
Mental Impairment	17 (.52%)
Eye	16 (.49%)
Depressed Mood Disorders	15 (.46%)
Enzyme	15 (.46%)
Ocular Sensory Symptoms	15 (.46%)
Salivary Gland Conditions	15 (.46%)
Anterior Eye Structural Change, Dep...	14 (.43%)
Lifestyle Issues	14 (.43%)
White Blood Cell	14 (.43%)
Myocardial	13 (.4%)
Angiedema And Urticaria	12 (.37%)
Musculoskeletal And Connective Tiss...	12 (.37%)
Oral Soft Tissue Conditions	12 (.37%)
Skin Vascular Abnormalities	12 (.37%)
Bone And Joint Injuries	11 (.34%)
Hearing	11 (.34%)
Hepatobiliary	11 (.34%)
Neuromuscular	11 (.34%)
Pleural	11 (.34%)
Viral Infectious	11 (.34%)
Sleep Disorders	10 (.31%)
Tissue	10 (.31%)
Neurological, Special Senses And Ps...	9 (.28%)
Skin Appendage Conditions	9 (.28%)
Dementia And Amnestic Conditions	8 (.25%)
Protein And Chemistry Analyses	8 (.25%)
Schizophrenia And Other Psychotic	8 (.25%)
Vascular Hemorrhagic	8 (.25%)
Water, Electrolyte And Mineral	8 (.25%)
Anemias Nonhemolytic And Marrow Dep...	7 (.22%)
Aneurysms And Artery Dissections	7 (.22%)
Gastrointestinal Hemorrhages	7 (.22%)
Gastrointestinal Inflammatory Condi...	7 (.22%)
Gastrointestinal Vascular Condition...	7 (.22%)
Glaucoma And Ocular Hypertension	7 (.22%)
Product Quality Issues	7 (.22%)
Structural Brain	7 (.22%)
Gastrointestinal Stenosis And Obstr...	6 (.18%)
Increased Intracranial Pressure And...	6 (.18%)
Microbiology And Serology	6 (.18%)
Neurological Disorders Of The Eye	6 (.18%)
Ocular Structural Change, Deposit A...	6 (.18%)
Respiratory And Pulmonary Investiga...	6 (.18%)
Toxicology And Therapeutic Drug Mon...	6 (.18%)
Bacterial Infectious	5 (.15%)
Platelet	5 (.15%)
Sexual Function And Fertility	5 (.15%)
Spleen, Lymphatic And Reticulendoth...	5 (.15%)
Therapeutic Procedures And Supporti...	5 (.15%)
Cardiac Therapeutic Procedures	4 (.12%)
Cardiac Valve	4 (.12%)
Changes In Physical Activity	4 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Atropine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Atropine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.